Navigation Links
Annual medical ethics conference celebrates 20 years of disputes
Date:11/10/2008

The 20th annual conference of The MacLean Center for Clinical Medical Ethics at the University of Chicago will honor the Center's founder and director, Mark Siegler, MD, and examine his work and influence on the field. The conference will be held at the University of Chicago Law School, 1111 E. 60th Street, on Fri., Nov 14 from 1 to 5 pm, and Sat., Nov. 15, from 7:30 am to 5:15 pm.

The conference will be a "festschrift"--a European tradition in which a scholar's colleagues and trainees honor him with a discussion of his work.

The conference is organized around 16 of Sielger's elegant and opinionated writings on the doctor-patient relationship, the development of the field of clinical medical ethics, improved end-of-life care for patients, and new ethical approaches to innovations in surgical can cancer care.

The Lindy Bergman Distinguished Service Professor of Medicine at the University, Siegler has written and spoken extensively on decision-making in complex medical situations, such as intensive care, end-of-life decision making and living-donor organ transplantation. These stressful situations serve as "clinical probes," he said. "They can help us understand the process by which patients and doctors reach everyday decisions."

Siegler founded The MacLean Center in 1984. It quickly became the country's leading center for teaching clinicians about patient-centered medical ethics. Since 1984, nearly 250 fellowsmost of them physicians, but also nurses, legal scholars, theologians, and philosophershave trained at the Center in a one- or two-year fellowship program.

Former MacLean fellows, many of who will speak at the conference, have published more than 60 books in the field. More than 30 have directed ethics programs in hospitals and research centers in the United States, Canada and Europe. More than 25 are now full professors at leading academic institutions and about a dozen hold endowed university professorships.'/>"/>

Contact: John Easton
john.easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
2. State of New Jersey Announces Intent to Award $50 Million Annual Transportation Contract to Providences LogistiCare Subsidiary
3. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
4. EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
5. Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
6. Masimo to Present at Lazard Capital Markets 5th Annual Healthcare Conference
7. Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales
8. Lung Cancer Alliance-Georgia Issues Third Annual State-Specific Report Card on Lung Cancer
9. HMS Holdings Corp. to Present at Credit Suisse Annual Global Healthcare Conference
10. Lung Cancer Alliance Releases 4th Annual Report Card on Lung Cancer
11. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2